贝瑞基因(000710) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥313,494,177.23, a decrease of 6.41% compared to ¥334,982,971.78 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥11,928,399.03, representing a decline of 156.15% from a profit of ¥21,242,485.44 in the previous year[3] - The basic and diluted earnings per share were both -¥0.04, a decline of 156.15% from ¥0.06 in the same period last year[3] - The company reported a net loss of CNY 12,217,400.42, compared to a net profit of CNY 20,948,311.58 in the same period last year[17] Cash Flow - The net cash flow from operating activities improved to -¥50,449,164.21, a 52.68% increase compared to -¥106,619,684.26 in the same period last year[3] - Cash received from operating activities decreased by 89.00% to ¥2,470,774.21, mainly due to last year's receipt of construction deposit from the Fujian Digital Life Industrial Park[6] - The company’s cash inflow from operating activities was CNY 385,442,573.36, while cash outflow was CNY 435,891,737.57[20] - The net cash flow from investment activities was -26,194,475.14 CNY, compared to -81,834,143.25 CNY in the previous year[21] - The cash inflow from financing activities totaled 41,593,432.70 CNY, down from 44,550,616.11 CNY year-over-year[21] - The cash outflow for debt repayment was 37,014,356.61 CNY, significantly lower than 66,343,351.00 CNY in the same period last year[21] - The net increase in cash and cash equivalents was -77,811,207.69 CNY, compared to -214,845,937.29 CNY in the previous year[21] - The ending balance of cash and cash equivalents was 340,078,087.38 CNY, down from 414,462,361.65 CNY year-over-year[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,443,319,312.21, down 2.17% from ¥3,519,721,822.69 at the end of the previous year[3] - The equity attributable to shareholders decreased by 0.81% to ¥2,470,145,379.24 from ¥2,490,192,733.55 at the end of the previous year[3] - The company’s total liabilities amounted to CNY 941,664,319.63, with total equity at CNY 2,501,654,992.58[13] - Current assets totaled CNY 1,823,816,977.26, down from CNY 1,906,579,870.07 at the start of the year, reflecting a decrease of approximately 4.3%[11] - Total non-current assets were CNY 1,619,502,334.95, a slight increase from CNY 1,613,141,952.62[12] - Current liabilities totaled CNY 717,179,038.88, down from CNY 768,577,015.73, reflecting a decrease of approximately 6.7%[12] Expenses - Total operating costs increased to CNY 309,299,721.50 from CNY 297,124,426.09, with sales expenses rising to CNY 68,195,926.23[16] - Financial expenses increased by 43.45% to ¥4,032,406.22, primarily due to interest payments on working capital loans[6] - Research and development expenses were CNY 26,127,459.15, down from CNY 31,015,909.78 in the previous period[16] Shareholder Information - The company reported a total of 10 major shareholders, with the largest being Chengdu Tianxing Instrument (Group) Co., Ltd. holding 12.41% of shares[10] Audit Status - The company’s first-quarter report was not audited[22]